Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea
· Delayed Price · Currency is KRW 29,000
+50 (0.17%)
Apr 29, 2026, 3:30 PM KST
Daihan Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 208,614 | 204,195 | 195,911 | 184,268 | 171,463 | Upgrade
|
| Other Revenue | -0 | - | - | - | -0 | Upgrade
|
| Revenue | 208,614 | 204,195 | 195,911 | 184,268 | 171,463 | Upgrade
|
| Revenue Growth (YoY) | 2.16% | 4.23% | 6.32% | 7.47% | 3.24% | Upgrade
|
| Cost of Revenue | 144,169 | 134,788 | 130,599 | 124,455 | 115,781 | Upgrade
|
| Gross Profit | 64,445 | 69,407 | 65,312 | 59,812 | 55,682 | Upgrade
|
| Selling, General & Admin | 30,014 | 28,428 | 26,945 | 25,445 | 24,923 | Upgrade
|
| Research & Development | 2,206 | 1,802 | 1,641 | 567.87 | 790.59 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | 0.5 | Upgrade
|
| Other Operating Expenses | 449.95 | 479.63 | 411.75 | 387.26 | 334.4 | Upgrade
|
| Operating Expenses | 33,259 | 31,327 | 29,517 | 26,844 | 26,614 | Upgrade
|
| Operating Income | 31,186 | 38,081 | 35,795 | 32,968 | 29,068 | Upgrade
|
| Interest Expense | -2.69 | -1.81 | -52.47 | -593.43 | -469.27 | Upgrade
|
| Interest & Investment Income | 1,867 | 1,475 | 87.18 | 486.66 | 506.7 | Upgrade
|
| Currency Exchange Gain (Loss) | -239 | 1,229 | 504.71 | 525.35 | 687.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 37.28 | 1,184 | 87.57 | 73.92 | 599.56 | Upgrade
|
| EBT Excluding Unusual Items | 32,848 | 41,967 | 36,422 | 33,461 | 30,392 | Upgrade
|
| Gain (Loss) on Sale of Investments | 274.01 | 303.6 | 288.69 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 31.38 | 58.03 | 22.53 | -9.4 | 41.28 | Upgrade
|
| Pretax Income | 33,153 | 42,329 | 36,734 | 33,451 | 30,433 | Upgrade
|
| Income Tax Expense | 5,510 | 8,569 | 8,307 | 8,491 | 7,763 | Upgrade
|
| Net Income | 27,644 | 33,759 | 28,426 | 24,961 | 22,670 | Upgrade
|
| Net Income to Common | 27,644 | 33,759 | 28,426 | 24,961 | 22,670 | Upgrade
|
| Net Income Growth | -18.11% | 18.76% | 13.88% | 10.10% | 30.43% | Upgrade
|
| Shares Outstanding (Basic) | - | 6 | 6 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | - | 6 | 6 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | - | - | -1.75% | -0.25% | - | Upgrade
|
| EPS (Basic) | - | 5741.34 | 4834.41 | 4170.67 | 3778.40 | Upgrade
|
| EPS (Diluted) | - | 5741.34 | 4834.41 | 4170.67 | 3778.40 | Upgrade
|
| EPS Growth | - | 18.76% | 15.92% | 10.38% | 30.43% | Upgrade
|
| Free Cash Flow | 481.53 | 19,841 | 17,580 | 20,378 | 28,767 | Upgrade
|
| Free Cash Flow Per Share | - | 3374.38 | 2989.79 | 3405.01 | 4794.57 | Upgrade
|
| Gross Margin | 30.89% | 33.99% | 33.34% | 32.46% | 32.48% | Upgrade
|
| Operating Margin | 14.95% | 18.65% | 18.27% | 17.89% | 16.95% | Upgrade
|
| Profit Margin | 13.25% | 16.53% | 14.51% | 13.55% | 13.22% | Upgrade
|
| Free Cash Flow Margin | 0.23% | 9.72% | 8.97% | 11.06% | 16.78% | Upgrade
|
| EBITDA | 40,406 | 45,362 | 44,459 | 42,176 | 40,479 | Upgrade
|
| EBITDA Margin | 19.37% | 22.21% | 22.69% | 22.89% | 23.61% | Upgrade
|
| D&A For EBITDA | 9,221 | 7,282 | 8,663 | 9,208 | 11,411 | Upgrade
|
| EBIT | 31,186 | 38,081 | 35,795 | 32,968 | 29,068 | Upgrade
|
| EBIT Margin | 14.95% | 18.65% | 18.27% | 17.89% | 16.95% | Upgrade
|
| Effective Tax Rate | 16.62% | 20.24% | 22.61% | 25.38% | 25.51% | Upgrade
|
| Advertising Expenses | 174.21 | 99.76 | 78.69 | 93.67 | 63.18 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.